Chairman and founding member of CSP who has raised over $1bn for various life sciences over his career. Previously, he founded and grew Circassia Pharmaceuticals into an international respiratory business including setting up direct sales operations in China. He is a founding member and Chairman of Synchrony Pharma. He was a founding member of the management team that grew ZeneusPharma into a successful specialty pharmaceutical company and managed its acquisition by Cephalon Inc. (now part of Teva).
CSP is a specialty pharmaceutical company focused on becoming the trusted and respected partner for pharma companies looking to develop and commercialise their products in China.
We take on all the responsibility for the clinical, regulatory and commercialisation of speciality and rare drugs in China to address the unmet medical needs of Chinese patients. At the same time, we are also looking to bring Chinese science to the West.
As a British company operating to western standards of quality and compliance our approach is to in-license Chinese rights and build a portfolio of innovative specialty assets.
Our team in the UK has deep expertise in China and is focused on identifying innovative de-risked products to address the unmet medical needs of Chinese patients. Our team based in China are experts in the clinical and regulatory development, and commercialisation of products.